MediciNova (MNOV) Starts Phase II Trial on MN-221

June 23, 2008 7:45 AM EDT

MediciNova, Inc. (Nasdaq: MNOV) and the Hercules Market of the Osaka Securities Exchange, today announced that it has initiated dosing in a Phase II clinical trial to determine the safety and efficacy of MN-221 in patients with moderate to severe, but stable asthma. This is the second Phase II trial currently underway to evaluate MN-221 in various populations of asthma patients.

This randomized, open-label, placebo-controlled Phase II clinical trial will involve approximately 15 to 25 patients in two dose cohorts at four clinical sites in the United States. Each patient will receive MN-221 at doses of up to 1,125 micrograms or placebo in a continuous intravenous infusion of up to two hours. Safety and preliminary efficacy data, including changes in forced expiratory volume in one second (FEV1), will be collected and summarized; however, the data will not be subjected to inferential statistical analysis. The data from this clinical trial, along with the other Phase II clinical trial in severe, acute exacerbations of asthma, will aid in the design of a larger Phase IIb Emergency Department clinical trial, which is anticipated to begin toward the end of 2008, as well as a future Phase III ED clinical trial.

MediciNova, Inc., a development-stage biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics principally in the United States.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?